Search

8 May 2024: MutREAD – Mutational Signature Detection byRestriction Enzyme-Associated DNA Sequencing. BACKGROUND. The successful application of mutational signatures in clinical settingsrequires availability of a cost-effective, scalable detection method that

8 May 2024: PredictImmune. PredictImmune. HELPING PATIENTS DIAGNOSED WITHCHRONIC IMMUNE-MEDIATED DISORDERS TOLIVE NORMAL AND HEALTHY LIVES. Website. Overview. PredictImmune developes prognostic assays that predict disease progression forpatients with

8 May 2024: Real-time autofocus for videomicroscopy. BACKGROUND. Video-microscopy of living subjects is hampered by their movement out of themicroscope’s focal plane. At video frame-rates, manual refocusing becomesimpossible; therefore, autofocus is required.

8 May 2024: Low-Cost Trace Analyte Detection with ReusableSERS Substrates. BACKGROUND. To move beyond current low-cost sensors, towards measuring trace analytes inapplications such as healthcare monitoring, geology and mineralogy, pollutionmonitoring, and

8 May 2024: Mouse Models of Essential Thrombocythemia(ET) and Myelofibrosis (MF) – Available forPreclinical Studies? Background. Researchers at the University of Cambridge have generated fully characterised,conditional knock-in mouse models for essential

8 May 2024: Implantable drug delivery device targeting braintumours. BACKGROUND. Successful treatment of brain cancers is limited due to the difficulty of deliveringtherapies to difficult-to-access tumours. There is also a need for new technologiesable to

8 May 2024: Ortho-quinone prodrug strategy (self-immolativelinkers). BACKGROUND. The para-quinones doxorubicin (Adriamycin),geldanamycin, mitoxantrone and mitomycin C have lowerredox-cycling rates than ortho-quinones and aresuccessfully used in the clinic.

8 May 2024: Polymer Masterbatch: Customized High-Performance Composite for Your Needs. BACKGROUND. Nanoparticle composites are a unique class of materials that combine nano-sizedparticles with a matrix material, creating polymers with new and improvedproperties

8 May 2024: Planarific: AI-based software for sustainableretrofitting and design. BACKGROUND. The UK has set an ambitious goal of achieving net zero carbon emissions by 2050,which requires a drastic reduction in the energy consumption and greenhouse

8 May 2024: Upcycling waste plastics with sunlight. BACKGROUND. Traditionally, the term “photoreforming” refers to the use of light energy to drive theconversion of waste feedstocks into sustainable fuels and / or chemicals, such asthe production of

8 May 2024: Versatile Electronic Fibre. BACKGROUND. Wearable electronics, such as smart textiles or e-textiles, are growing fields due totheir potential application in healthcare monitoring, consumer electronics, energyharvesting and storage, and sensing. For

8 May 2024: Cambridge Centre for Resilience andSustainable Development. BACKGROUND. At the Centre for Resilience and Sustainable Development CRSD we bring togetherleaders from the public, private and third sectors with academic thought leaders tocreate robust

8 May 2024: Matta. Matta. BUILDING AI TO MANUFACTURE THEIMPOSSIBLE. Website. Overview. At Matta we are building the AI operating system for additive manufacturing. Ourtechnology is based on state-of-the-art research by engineers and scientists atCambridge. We

8 May 2024: Phase engineering of 2D materials. BACKGROUND. 2D materials have many unique properties such as high surface area, exceptionalmechanical strength, and excellent electrical and thermal conductivity. Transitionmetal dichalcogenides (TMDs) e.g.

8 May 2024: Sustainable Investment Markers Tool: 9SIMS. BACKGROUND. Lack of integration between environmental, social, and governance (ESG) factors incorporate reporting creates opportunities for greenwashing. This is because goodperformance in one ESG indicator

8 May 2024: Cambridge Policy Boot Camp – CPBC. BACKGROUND. Complex systems theory, political science, sustainability science, and participatoryresearch all offer valuable tools and insights for decision makers – but are too oftensiloed or locked away in

8 May 2024: Bamboo cricket bat. BACKGROUND. This innovative bat combines its high-performance properties with the sustainablecredentials which derive from fast growing and widespread bamboo. DEVELOPED BY RESEARCHERS FROM CAMBRIDGE'S CENTRE FOR NATURAL MATERIAL

8 May 2024: Scalable Production of High-Quality PrintableGraphene. BACKGROUND. Printable electronics are a promising field of research whose technical developmentis focused on conductive-ink printing technologies appropriate for a wide range ofsupport materials

8 May 2024: Single vessel green ammonia production. BACKGROUND. Ammonia is the second-largest globally produced chemical ( 240 milliontons/year), mainly used as fertiliser, feeding over 50% of the World’s population.Currently, (brown/grey) ammonia is produced

8 May 2024: Blood flow digital twin from a rapid MRI scan. BACKGROUND. Flow-MRI allows clinicians to visualise flows in the body in 4D (3 spatial and 1 timedimension) without using ionising radiation. Currently, scans take tens of minutesand require the patient

8 May 2024: Flexible wooden walls. BACKGROUND. The way we construct indoor spaces for people is currently flawed. Thepermanence of current buildings limits people’s freedom to change theirsurroundings and restricts their ability to adapt to impermanent ways

8 May 2024: H2Upgrade – H2 from industrial waste. BACKGROUND. Waste generation is a common challenge faced by numerous industries,manifesting as waste gases, liquids, or solid residues from processes, reactions,equipment cleaning, or combustion. The safe

8 May 2024: Transforming Pedagogical Practices forAcademic Success (TransPAS). CONTEXT. China is a multilingual country with over 280 languages spoken by its 56 ethnicgroups. While Mandarin Chinese is promoted as the national lingua franca, thegovernment has

8 May 2024: Microparticle production platform technology(DropShell). BACKGROUND. Engineered microparticles are ubiquitous in many commercial products, fromagritech to nutraceuticals and cosmetics. In the pharmaceutical industry, controlledencapsulation and

8 May 2024: KARPAS 299 Lymphoma Cell LineHuman Non-Hodgkin's Ki-positive Large Cell Lymphoma cell lines. KARPAS 299 Human Non-Hodgkin’s Ki-positive Large Cell Lymphoma cell line useful inoncology research, developed at the University of Cambridge. Cambridge

8 May 2024: LGR5 monoclonal antibody for cancerimmunotherapy. BACKGROUND. In 2020, there were 1.9 million new cases of colorectal cancer, which is the 3rdmost common cancer worldwide. Liver cancer and Leukaemia are the 6th and 13th. most common cancer types,

22 May 2023: Guide to using free images Research Communications Team, Office of External Affairs and Communications. When sourcing free images from the web to illustrate your own site, there are a number of issues that. you should consider. Some of these are

8 May 2024: MAT2A inhibitors to treat BK polyomavirusdisease. BACKGROUND. BKPyV is a pervasive human pathogen which resides within the reno-urinary tractin 80-90% of the population. It is asymptomatic in healthy individuals; however, itposes a significant

8 May 2024: Electronic nose. BACKGROUND. This technology “represents a considerable advance in the state-of-the-art…Highly original and building from a sparse amount of previous research”-Prof Krishna Persaud, e-nose pioneer. What would we recognise if

5 Feb 2021: Ask family or colleagues not to download or stream films, play online games or download files during the broadcast.

8 May 2024: CAM2 hearing aid fitting softwareCAM2 software is a package that enables hearing aids to be tailored to anindividual’s needs, resulting in improved hearing quality. All modern hearing aids include multi-channel amplitude compression and the

8 May 2024: KARPAS 929 Human Myeloma cell line. KARPAS 929 Human Myeloma cell line, developed at the University of Cambridge, useful inoncology research. Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. Wehave partnered

8 May 2024: KARPAS 417 Human Myeloma cell line. KARPAS 417 Human Myeloma cell line useful in oncology research, developed at the Universityof Cambridge. Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. Wehave partnered

13 May 2014: www.understandinganimalresearch.org.uk/. media-library/download/document/145/. THE STATUS OF THE CONCORDAT. This Concordat has been developed.

8 May 2024: KARPAS 1272 Human Myeloma cell line. KARPAS 1272 Human Myeloma cell line useful in oncology research, developed at theUniversity of Cambridge. Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. Wehave

8 May 2024: KARPAS 707H Human Myeloma cell line. KARPAS 707H Human myeloma cell line suitable for the generation of stable humanhybridomas for the creation of fully human monoclonal antibodies. Cambridge Enterprise Limited is the exclusive licensor for the

19 Nov 2020: Cambridge University research connected with reproduction

8 May 2024: Rat CD45 monoclonal antibody YTH 24.5. Hybridoma cell line producing YTH 24.5 antibodies raised against human CD45 which are ratmonoclonal antibodies of the IgG2b isotype. AuthorsHerman Waldmann. ReferencesC I Bindon, G Hale, M Clark, H

18 Oct 2016:

8 May 2024: Human CD7 monoclonal antibody YTH30.15. Hybridoma cell line producing YTH 30.15 antibodies raised against human CD7 which are ratmonoclonal antibodies of the IgG2b isotype.

8 May 2024: Human CD59 monoclonal antibody YTH53.1. Hybridoma cell line producing YTH 53.1 antibodies raised against human CD59 which are ratmonoclonal antibodies of the IgG2b isotype. https://licensing.enterprise.cam.ac.uk/product/human-cd59-monoclonal-antibody

8 May 2024: KARPAS 241 Human Monoblastic cell line. KARPAS 241 Human Monoblastic cell line useful in oncology research, developed at theUniversity of Cambridge. Cambridge Enterprise Limited is the exclusive licensor for the Karpas cell line portfolio. Wehave

8 May 2024: Human CD11a monoclonal antibody YTH81.5. Hybridoma cell line producing YTH 81.5 antibodies raised against human CD11a which are ratmonoclonal antibodies of the IgG2a isotype.

8 May 2024: Mouse CD71 monoclonal antibody YTA74.4.4. Hybridoma cell line producing YTA 74.4.4 antibodies raised against mouse CD71 which aremonoclonal antibodies of the IgG2a isotype. Has been used in CD4 subset depletion in vivoand flow cytometry studies.

8 May 2024: Mouse CD18 monoclonal antibody YTS213.1.1. Hybridoma cell line producing YTS 213.1.1 antibodies raised against mouse CD18 which are ratmonoclonal antibodies of the IgG2a isotype. AuthorsHerman Waldmann.

8 May 2024: Human CD28 monoclonal antibody YTH913.12. Hybridoma cell line producing YTH 913.12 antibodies raised against human CD28 which are ratmonoclonal antibodies of the IgG2b isotype.

8 May 2024: Rat IgG2b monoclonal antibody NORIg7.16.2. Hybridoma cell line against rat IgG2b, producing NORIg 7.16.2 antibodies which are mousemonoclonal antibodies. AuthorsHerman Waldmann. ReferencesG Hale; M Clark; H Waldmann(1 May

5 Feb 2021: Ask family or colleagues not to download or stream films, play online games or download files during the broadcast.

8 May 2024: Human CD45R monoclonal antibody YTH80.103. Hybridoma cell line producing YTH 80.103 antibodies raised against human CD45R which arerat monoclonal antibodies of the IgG2b isotype. AuthorsHerman Waldmann. ReferencesG Hale; M Clark; H Waldmann(May 1st

8 May 2024: FcgRlla 131H receptor expressing cell line. CHO cells transfected to express human FcgRlla allotype 131H as a transmembrane proteinwith its native intracellular domain. Useful for investigation of the binding of recombinantantibodies to human Fc